Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06508320 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)
A Phase 2 study, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 2
- Development phase
- 932
- Enrollment target
NCT06508320 is a Phase 2 study that has completed, run by ModernaTX. The registered enrollment target is 932 participants.
The verdict
NCT06508320, a Phase 2 study, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 932 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity in relation to the product attributes of mRNA-1083 vaccine when administered as a single intramuscular (IM) injection in adults ≥50 to \<65 years of age.
Interventions
- BIOLOGICAL mRNA-1083
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 932 participants |
| Start Date | 2024-07-15 |
| Est. Completion | 2025-09-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06508320
The ClinicalTrials.gov registry entry for NCT06508320 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 932 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which mRNA-1083 is the first listed.
NCT06508320 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06508320 about?
NCT06508320 is a clinical study titled "A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)". The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity in relation to the product attributes of mRNA-1083 vaccine when administered as a single intramuscular (IM) injection in adults ≥50 to \<65 years of age.
What is the current status of trial NCT06508320?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 932 participants. The study started on 2024-07-15. Estimated completion is 2025-09-25.
What interventions are being tested in trial NCT06508320?
The interventions under investigation include: mRNA-1083 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06508320?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.